Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, open-label, monotherapy and combination therapy long-term study of imeglimin (TIMES 2)

Trial Profile

A phase III, open-label, monotherapy and combination therapy long-term study of imeglimin (TIMES 2)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Imeglimin (Primary) ; Alpha-glucosidase inhibitors; Antihyperglycaemics; Biguanides; CD26 antigen inhibitors; Glucagon-like peptide 1 agonist; Sodium-glucose transporter 2 inhibitors; Sulfonylureas; Thiazolidinediones
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms TIMES 2
  • Sponsors Cmic; Poxel; Sumitomo Dainippon Pharma
  • Most Recent Events

    • 08 Oct 2018 According to a Poxel media release, results are anticipated in the second half of 2019
    • 02 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 03 Jul 2018 According to Poxel media release, enrollment of this trial is expected to during the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top